BD (Becton, Dickinson and Company) announced on January 9, 2025, the results of a new survey revealing that 72% of women in the United States have delayed gynecology visits. The survey, conducted by The Harris Poll, found that 54% cited fear or discomfort and 49% cited scheduling challenges as reasons for delay.
Despite 62% of women understanding that cervical cancer is preventable with regular screenings, 81% expressed a desire for more comfortable and less invasive HPV/cervical cancer testing options than a pelvic exam. Furthermore, 73% were interested in using a self-collection vaginal swab test at the doctor's office.
These findings underscore the market need for solutions like the BD Onclarity™ HPV Assay, which is FDA-approved for self-collection and identifies more individual high-risk HPV types. This targeted approach aims to ensure appropriate care and reduce unnecessary invasive tests, aligning with recommendations from various national and international agencies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.